Jingsheng Hua

Taizhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors.

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors.

Journal: Journal of visualized experiments : JoVE

Published: November 03, 2025

Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer.

Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer.

Journal: Journal of materials science. Materials in medicine

Published: October 16, 2025

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

Journal: iScience

Published: September 14, 2025

Global, regional, and National burden of metabolic dysfunction-associated steatohepatitis-related liver cancer in older adults: trends and cross-national inequality based on the global burden of disease study 2021.

Global, regional, and National burden of metabolic dysfunction-associated steatohepatitis-related liver cancer in older adults: trends and cross-national inequality based on the global burden of disease study 2021.

Journal: Discover oncology

Published: March 21, 2025

Innovative Applications of Bacteria and Their Derivatives in Targeted Tumor Therapy.

Innovative Applications of Bacteria and Their Derivatives in Targeted Tumor Therapy.

Journal: ACS nano

Published: January 28, 2025

Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies

Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: April 11, 2024

High FAAP24 expression reveals poor prognosis and an immunosuppressive microenvironment shaping in AML.

High FAAP24 expression reveals poor prognosis and an immunosuppressive microenvironment shaping in AML.

Journal: Cancer cell international

Published: February 08, 2023

Comprehensive analysis of ERCC3 prognosis value and ceRNA network in AML.

Comprehensive analysis of ERCC3 prognosis value and ceRNA network in AML.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 30, 2022

A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.

A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.

Journal: Frontiers in immunology

Published: September 09, 2022

Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study.

Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 14, 2021

Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.

Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation

Published: May 24, 2020

Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.

Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 19, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026